Bladder cancer: toward state of the art multidisciplinary molecular medicine.
Recent advances in bladder cancer research, and clinical diagnosis and therapy are explored. Major advances in biologic understanding are applied toward better early diagnosis and staging. Using molecular medicine to help informed clinical trial design and implementation will lead to more effective therapeutic intervention in transitional cell carcinoma. Interdisciplinary care and multimodal approach will allow better outcomes, stage for stage and grade for grade. The challenge is for clinician-scientists to integrate basic and translational advances efficiently and rapidly into the clinic, recognizing the value of a multifaceted paradigm.
Rashid
Hani H
HH
Center for Prostate Cancer, Department of Urologic Surgery, University of Minnesota Comprehensive Cancer Center, Minneapolis, MN, USA.
Koeneman
Kenneth S
KS
D003131:Combined Modality Therapy; D006801:Humans; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000628:therapy*